Fulvestrant
- Generic Name
- Fulvestrant
- Brand Names
- Faslodex, Fulvestrant Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47F5O3S
- CAS Number
- 129453-61-8
- Unique Ingredient Identifier
- 22X328QOC4
- Background
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor. While it is used as monotherapy for the treatment of breast cancers, it is also used in combination with alpelisib for the treatment of HR-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
- Indication
For the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy, as monotherapy or in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Breast Cancer, Advanced or Metastatic Breast Cancer
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
- Conditions
- Low Grade Ovarian Serous Adenocarcinoma
- Interventions
- Drug: nab-Sirolimus
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- University of Oklahoma
- Target Recruit Count
- 37
- Registration Number
- NCT06494150
- Locations
- 🇺🇸
OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06428396
- Locations
- 🇨🇴
IMAT S.A.S ( Site 1205), Monteria, Cordoba, Colombia
🇨🇦Jewish General Hospital ( Site 0400), Montreal, Quebec, Canada
🇬🇧Ipswich Hospital ( Site 1911), Ipswich, Suffolk, United Kingdom
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 15
- Registration Number
- NCT06409390
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
- Conditions
- Hormone Receptor-positive Human Epidermal Growth Factor 2-negativeMetastatic Invasive LObular Carcinoma
- Interventions
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT06408168
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
A Retrospective Real-world Study of Abemaciclib in HR+ Breast Cancer
- Conditions
- Breast CancerBreast DiseasesNeoplasms
- Interventions
- First Posted Date
- 2024-04-02
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- The Affiliated Hospital of Qingdao University
- Target Recruit Count
- 200
- Registration Number
- NCT06341283
- Locations
- 🇨🇳
Clinical Research Center, Qingdao, Shandong, China
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
- Conditions
- Breast CancerSmall Cell Lung CancerOvarian CancerGastric CancerHormone-receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast CancerAdvanced Solid TumorEndometrial CancerProstate CancerTNBC - Triple-Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 218
- Registration Number
- NCT06257264
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇺🇸Hoag Memorial Presbyterian, Newport Beach, California, United States
🇺🇸Florida Cancer Specialists and Research Institute, Lake Mary, Florida, United States
BGB-43395 Alone or as Part of Combination Therapies in Chinese Participants With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Conditions
- Advanced Solid TumorMetastatic Solid TumorHormone-receptor-positive Breast CancerBreast CancerMetastatic Breast CancerHormone Receptor Positive Malignant Neoplasm of BreastHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 33
- Registration Number
- NCT06253195
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
- Conditions
- Advanced CancerBreast Cancer
- Interventions
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- OnKure, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06239467
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence, Encinitas, California, United States
🇺🇸University of California San Diego UCSD, La Jolla, California, United States
🇺🇸UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
- Target Recruit Count
- 306
- Registration Number
- NCT06208410
- Locations
- 🇨🇳
Henan Provincial Cancer Hospital, Zhengzhou, Henan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.